// App-Quantinova.ai

171 : Secukinumab provides sustained PASDAS related low disease activity in psoriatic arthritis: two year results from the FUTURE 2 study

Researchers

Presenter

  • Laura C Coates

Principal Investigators

  • Dafna Gladman

  • Peter Nash

  • Oliver Fitzgerald

  • Arthur Kavanaugh

  • Lawrence Rasouliyan

  • Luminita Pricop

  • Kevin Ding

  • Corine Gaillez

Medical Centers

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

  • Toronto General Hospital, University of Toronto, Toronto, ON, Canada

  • Faculty of Medicine, University of Queensland, Brisbane, AUSTRALIA

  • Rheumatology, St Vincent’s University Hospital and Conway Institute, University College Dublin, Dublin, IRELAND

  • Rheumatology, Allergy and Immunology, UC San Diego School of Medicine, La Jolla, CA, USA

  • Biostatistics, RTI Health Solutions, Barcelona, Spain,

  • Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ

  • Immunology, Dermatology and Rheumatology/Autoimmunity, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • Canada

  • Australia

  • Ireland

  • United States

  • Spain

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved